Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) ROCE % : 23.61% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Yichang HEC ChangJiang Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 23.61%.

Yichang HEC ChangJiang Pharmaceutical Co ROCE % Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co ROCE % Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

43.29

20.02

-5.83

3.74

30.36

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial														1.07	2.43	6.24	37.58	23.61

Yichang HEC ChangJiang Pharmaceutical Co ROCE % Calculation

Yichang HEC ChangJiang Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2574.94	/	( ( (13277.515 - 5517.443)	+	(13939.478 - 4738.491) )	/ 2 )
	=	2574.94	/	( (7760.072	+	9200.987)	/ 2 )
	=	2574.94	/	8480.5295
	=	30.36 %

Yichang HEC ChangJiang Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	2091.41	/	( ( (14705 - 6188.387)	+	(13939.478 - 4738.491) )	/ 2 )
	=	2091.41	/	( ( 8516.613	+	9200.987 )	/ 2 )
	=	2091.41	/	8858.8
	=	23.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Yichang HEC ChangJiang Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN

Website

http://www.hec-changjiang.com

Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines